Synergistic and Antagonistic Drug Combinations against SARS-CoV-2-Reference-Cited by-同舟云学术

Synergistic and Antagonistic Drug Combinations against SARS-CoV-2

Published:2021-02 Issue:2 Volume:29 Page:873-885
ISSN:1525-0016
Container-title:Molecular Therapy
language:en
Short-container-title:Molecular Therapy

Author:

Bobrowski Tesia,Chen Lu,Eastman Richard T.,Itkin Zina,Shinn Paul,Chen Catherine Z.,Guo Hui,Zheng Wei,Michael Sam,Simeonov Anton,Hall Matthew D.,Zakharov Alexey V.,Muratov Eugene N.^ORCID

Funder

National Institutes of Health

National Center for Advancing Translational Sciences

Publisher

Elsevier BV

Subject

Drug Discovery,Pharmacology,Genetics,Molecular Biology,Molecular Medicine

Reference50 articles.

1. The hepatitis C virus (HCV) NS4B RNA binding inhibitor clemizole is highly synergistic with HCV protease inhibitors;Einav;J. Infect. Dis.,2010

2. Synergistic drug combination effectively blocks Ebola virus infection;Sun;Antiviral Res.,2017

3. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies;Chou;Pharmacol. Rev.,2006

4. High-Throughput Methods for Combinatorial Drug Discovery;Sun;Sci. Transl. Med,2013

5. Scaffold morphing of arbidol (umifenovir) in search of multi-targeting therapy halting the interaction of SARS-CoV-2 with ACE2 and other proteases involved in COVID-19;Choudhary;Virus Res.,2020

Cited by 81 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hyphenating sustainability with chemometrics in chromatographic analysis of COVID combo therapy, nirmatrelvir and Molnupiravir, in presence of their overlapping degradation products; blue-green dual evaluation tools;Journal of Chromatography B;2024-10

2. Drupacine as a potent SARS-CoV-2 replication inhibitor in vitro;Biosafety and Health;2024-09

3. Deep learning for predicting synergistic drug combinations: State‐of‐the‐arts and future directions;Clinical and Translational Discovery;2024-06

4. A combination of nirmatrelvir and ombitasvir boosts inhibition of SARS-CoV-2 replication;Antiviral Research;2024-05

5. Research Progress on Spike-Dependent SARS-CoV-2 Fusion Inhibitors and Small Molecules Targeting the S2 Subunit of Spike;Viruses;2024-04-30